Lixte Biotechnology Files 8-K

Ticker: LIXT · Form: 8-K · Filed: Aug 19, 2025 · CIK: 1335105

Sentiment: neutral

Topics: 8-k, corporate-filing, financials

Related Tickers: LIXT

TL;DR

LIXT filed an 8-K on 8/18/25 covering other events and financials.

AI Summary

Lixte Biotechnology Holdings, Inc. filed an 8-K on August 18, 2025, reporting other events and financial statements. The company, incorporated in Delaware, has its principal executive offices in Pasadena, California, with a contact phone number of (631) 830-7092. The filing also lists common stock and warrants to purchase common stock.

Why It Matters

This 8-K filing provides an update on Lixte Biotechnology's corporate activities and financial reporting, which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of August 18, 2025.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on August 18, 2025.

What is Lixte Biotechnology Holdings, Inc.'s Commission File Number?

Lixte Biotechnology Holdings, Inc.'s Commission File Number is 001-39717.

Where are Lixte Biotechnology Holdings, Inc.'s principal executive offices located?

Lixte Biotechnology Holdings, Inc.'s principal executive offices are located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.

What is the IRS Employer Identification Number for Lixte Biotechnology Holdings, Inc.?

The IRS Employer Identification Number for Lixte Biotechnology Holdings, Inc. is 20-2903526.

Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-08-18 18:04:30

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) Date: August 18, 2025 By: /s/ GEORDAN PURSGLOVE Geordan Pursglove Chief Executive Officer INDEX TO EXHIBITS Exhibit No. Description 99.1 News release to provide an update with respect to recent corporate activities and developments. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing